Receptors for regulatory peptides are overexpressed in a variety of human cancers. They represent the molecular basis for in vivo imaging with radiolabeled peptide probes. Somatostatin-derived tracers, designed to image the sst2-overexpressing neuroendocrine tumors, have enjoyed almost 2 decades of successful development and extensive clinical applications. More recent developments include second- and third-generation somatostatin analogs, with a broader receptor subtype profile or with antagonistic properties. Emerging tracers for other peptide receptors, including cholecystokinin/gastrin and GLP-1 analogs for neuroendocrine tumors, bombesin and neuropeptide-Y analogs for prostate or breast cancers, or Arg-Gly-Asp peptides for neoangiogenesis labeling, are also in current development. Application fields include both SPECT/CT and PET/CT. Copyright © 2008 by the Society of Nuclear Medicine, Inc.
CITATION STYLE
Reubi, J. C., & Maecke, H. R. (2008, November 1). Peptide-based probes for cancer imaging. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.108.053041
Mendeley helps you to discover research relevant for your work.